S. Ansell

478 citations
13 papers · 352 indexed · h-index 8

S. Ansell

12 papers receiving 347 citations

Peers

S. Ansell
Comparison fields: 5 of 57
  • Pathology and Forensic Medicine 167
  • Immunology 162
  • Oncology 158
  • Genetics 58
  • Dermatology 38
Replace Annette Grummels with:
Annette Grummels Netherlands
Francesca Montanari Italy
T Beck United States
Cristiane Milito Brazil
T Papadaki Greece
Yukinao Ishibashi Japan
K Takagi Japan
Huiqiang Huang China
Thérèse Aurran‐Schleinitz France
Helmut Renner Germany
S. Ansell relative to Annette Grummels Netherlands Annette Grummels's profile →
Citations per field
00.5×2.9×
Annette Grummels · 1×
Citations per year

Countries citing papers authored by S. Ansell

Since Specialization
Citations

This map shows the geographic impact of S. Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Ansell more than expected).

Fields of papers citing papers by S. Ansell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Ansell. The network helps show where S. Ansell may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. Ansell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Ansell Line = papers co-authored together S. Ansell links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1 20191
2 201635
3
CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
20163
4
CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
20161
5 201579
6 201221
7 20090
8 20088
9 20082
10 200723
11 200246
12 1997112
13 199221

About S. Ansell

S. Ansell is a scholar working on Pathology and Forensic Medicine, Genetics and Radiation, having authored 13 papers that have together received 352 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (3 papers), Lung Cancer Treatments and Mutations (2 papers), Advanced Radiotherapy Techniques (2 papers), PI3K/AKT/mTOR signaling in cancer (1 paper), Acute Myeloid Leukemia Research (1 paper), T-cell and Retrovirus Studies (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (167 citations), Immunology (162 citations) and Oncology (158 citations). S. Ansell has collaborated with scholars based in United States, Canada and Poland. Frequent co-authors include Thomas M. Habermann, Paul J. Kurtin, C Y Li, David J. Inwards, Thomas E. Witzig, Joseph P. Colgan, Anne J. Novak, TE Witzig, Steven C. Ziesmer and Michael P. Gustafson. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and Medical Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026